Tissue Regenix Group PLC HTA License granted and UK distribution Agreement (3185S)
June 25 2018 - 2:00AM
UK Regulatory
TIDMTRX
RNS Number : 3185S
Tissue Regenix Group PLC
25 June 2018
Tissue Regenix Group plc
HTA license granted for import of CellRight Technologies'
products into the UK
First commercial distribution agreement signed in UK
Leeds, 25 June 2018 - Tissue Regenix Group (AIM:TRX) ("Tissue
Regenix" or "The Group") the regenerative medical devices company
announces that it has been granted a Human Tissue Authority (HTA)
license to import and distribute its' portfolio of Human tissue
derived products from the US for use in the UK market. To drive
commercial execution The Group has also signed a long term,
non-exclusive UK distribution agreement with Pennine Healthcare
Limited ("Pennine").
HTA License
The HTA license will initially be used for the import of the
CellRight 'BioRinse' portfolio of osteoinductive bone products from
the San Antonio, Texas manufacturing facility into the UK.
UK Distribution Agreement Signed
Demand for osteoinductive regenerative medicine continues to
increase in the UK. In order to access the market effectively, the
Group has signed a three-year, non-exclusive distribution agreement
with Pennine.
Pennine is one of the UKs leading privately owned manufacturers
and distributors of medical devices. With an established presence
in the UK Orthopaedic market, the agreement with Pennine will
enable Tissue Regenix to further penetrate the UK orthopaedic spine
market. Under the terms of the agreement, Pennine will have access
to Tissue Regenix portfolio of novel bone and soft tissue products,
which will complement Pennine's existing range of spinal
implants.
Steve Couldwell, CEO, Tissue Regenix Group plc, commented:
"Receiving the HTA license is a pivotal milestone as we complete
the integration of CellRight into the Group. This allows us to
import the BioRinse portfolio in to the UK and ultimately, over
time, distribute throughout Europe to meet increasing demand for
our novel regenerative medicines. The HTA license provides the
flexibility to import, store and distribute our portfolio of
innovative products, a key commercial growth driver for the Group
in the future."
For more Information:
Tissue Regenix Group plc Tel: 0330
Caitlin Pearson Head of Communications 430 3073 /
07920272 441
---------------------------------------- --------------
Jefferies International Ltd Tel: 020 7029
Simon Hardy / Christopher Binks 8000
---------------------------------------- --------------
FTI Consulting Tel: 0203
Brett Pollard / Mo Noonan/ Rob Winder 727 1000
======================================== ==============
About Tissue Regenix
Tissue Regenix is a leading medical devices company in the field
of regenerative medicine. Tissue Regenix was formed in 2006 when it
was spun-out from the University of Leeds, UK. The company's
patented decellularisation ('dCELL(R) ') technology removes DNA and
other cellular material from animal and human soft tissue leaving
an acellular tissue scaffold which is not rejected by the patient's
body and can then be used to repair diseased or worn out body
parts. Current applications address many critical clinical needs
such as sports medicine, heart valve replacement and wound
care.
In November 2012 Tissue Regenix Group plc set up a subsidiary
company in the United States - 'Tissue Regenix Wound Care Inc.',
January 2016 saw the establishment of joint venture GBM-V, a multi-
tissue bank based in Rostock, Germany.
In August 2017 Tissue Regenix acquired CellRight Technologies(R)
, a biotech company that specializes in regenerative medicine and
is dedicated to the development of innovative osteoinductive and
wound care scaffolds that enhance healing opportunities of defects
created by trauma and disease. CellRight's human osteobiologics may
be used in spine, trauma, general orthopedic, foot & ankle,
dental, and sports medicine surgical procedures.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
CNTFIMMTMBBTBFP
(END) Dow Jones Newswires
June 25, 2018 02:00 ET (06:00 GMT)
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Sep 2023 to Sep 2024